Abstract
Skin damage results from the natural aging process, physical wear and tear, UV light, and environmental pollutants. Centella asiatica (Cica) is a widely used traditional medicinal herb and is known to have therapeutic effects on skin and wound healing. This study aims to evaluate the effects of Kristen Claire Supreme Rejuvenation Essence® with Cica EV as the main active ingredient, on facial appearance and skin quality in healthy participants. Twenty healthy participants (4 males and 16 females; average age 36.5) were enrolled and underwent a 24-hour skin patch test on the forearm to assess potential irritation or allergic reactions. The test product was applied twice daily for 28 days. Facial skin quality assessments were conducted before use and at 7, 14, 21, and 28 days of product application. Measured parameters included skin hydration, melanin content, skin elasticity, wrinkle percentage, redness area percentage, and pore percentage. After 28 days of test product treatment, significant improvements were observed in skin hydration and elasticity, wrinkle, redness, and pore distribution, while skin melanin content was reduced significantly. Kristen Claire Supreme Rejuvenation Essence® effectively improved skin hydration, elasticity, and texture, brightened the complexion, and showed potential in slowing skin aging, making it a promising candidate for skincare applications.
Competing Interest Statement
C.-C. W., C.-H. C., P.-L. K., W.-H. T., L. T.-C. L., C. C., and T.-Y. K. are employees of Schweitzer Biotech Company. T.-M. C. and S.-S. W. have no competing interests to declare.
Clinical Trial
NCT06850935
Funding Statement
This study and the test product were funded and provided by Schweitzer Biotech Company.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The final protocol, case report form, and informed consent form were reviewed and approved by the institutional review board of the Antai Tian-Sheng Memorial Hospital (IRB No. 24-064-A, approved May 16, 2024).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data generated or analyzed during this study are included in this manuscript.
